HD Tirsema 44 Pen

HD Tirsema 44 Pen: Dual Peptide Weight Loss Injection

The HD Tirsema 44 Pen is a once-weekly subcutaneous injection containing 40 mg tirzepatide plus 4 mg semaglutide in a single device, marketed in South Africa via Beskinny (from R2400 per pen as of 2026 — confirm the current price on the product page). It targets adults who have already trialled single-peptide GLP-1 therapy and want a stronger combined GLP-1 and GIP receptor stimulus in one shot rather than two separate pens. Note that the combined product itself has not been evaluated in any published clinical trial; the evidence below is drawn from studies of tirzepatide and semaglutide administered individually.

The rationale is a shift in receptor occupancy. Tirzepatide is a dual GIP/GLP-1 receptor agonist with lower relative GLP-1 receptor engagement than a selective GLP-1 agonist, so adding 4 mg semaglutide is intended to raise the GLP-1 signal while leaving the GIP arm intact. This is a pharmacology-based hypothesis, not a proven combined-product effect.

Key Takeaways

• Tirsema 44 combines 40 mg tirzepatide and 4 mg semaglutide with the aim of dual GIP/GLP-1 receptor activation; it is positioned for users who have plateaued on single-peptide therapy.
• No peer-reviewed human trial of concurrent tirzepatide + semaglutide has been published. The combined product is investigational and is not registered with SAHPRA.
• Because no product insert exists for the combination, any titration is extrapolated from the FDA-approved tirzepatide prescribing information and must be set by a prescriber.
• GLP-1-naive users, those with prior severe GI side effects, and anyone with a history of medullary thyroid carcinoma or pancreatitis should not use this pen.
• Storage requires 2–8°C refrigeration until first use, then below 30°C for the in-use period; freezing irreversibly damages both peptides.

What Is the HD Tirsema 44 Pen?

The HD Tirsema 44 Pen is a once-weekly subcutaneous injection from HD Labs containing 44 mg of combined peptides per pen: 40 mg tirzepatide and 4 mg semaglutide, delivered via a prefilled multi-dose pen. It is intended for dual GIP and GLP-1 receptor stimulation aimed at appetite suppression and metabolic support. It is sold in South Africa through Beskinny (from R2400 per pen as of 2026).

The 44 mg total peptide load is the highest in HD Labs’ weight-loss pen range as of 2026. It sits above single-peptide options like the HD Labs Tirzepatide 30 Pen and in-catalogue alternatives such as the Body Pharm Tirzepatide 30 Pen. The “44” in the product name refers to that combined milligram total, not a concentration or strength grade.

Why Combine Tirzepatide and Semaglutide?

The idea behind combining tirzepatide and semaglutide is broader signalling coverage than either alone, because the two peptides engage appetite-regulating receptors with different binding profiles. This remains a hypothesis: it has not been tested in a published trial of the two given together.

Tirzepatide is a dual GIP/GLP-1 receptor agonist. Semaglutide is a selective GLP-1 receptor agonist. Adding a selective GLP-1 agonist is intended to increase GLP-1 receptor occupancy in the hypothalamic and brainstem centres that regulate satiety. Whether that translates into additional weight loss in humans, over and above tirzepatide alone, has not been demonstrated.

The individual evidence base is strong but separate. Tirzepatide’s weight-loss efficacy was established in SURMOUNT-1 (registered as NCT04184622), which reported roughly 20.9% mean body-weight reduction at the 15 mg weekly dose over 72 weeks. Semaglutide’s was established in the STEP-1 trial (registered as NCT03548935) at 2.4 mg weekly. There is no published human trial of concurrent tirzepatide + semaglutide administration as of 2026, so the dual-pen rationale rests on receptor-pharmacology inference, not head-to-head outcomes data. That gap matters when weighing Tirsema 44 against a single-peptide option like the HD Labs Tirzepatide 30 Pen or the Body Pharm Tirzepatide 30 Pen.

Where the combination logic could break down

Because tirzepatide already activates the GLP-1 receptor, layering semaglutide on top may add redundancy rather than a distinct pathway. The counter-argument is that partial GLP-1 occupancy could leave room for an additive selective agonist. Both positions are theoretical: without direct combination-trial data, neither the added benefit nor the added risk of stacking the two peptides has been quantified in humans.

HD Tirsema 44 vs Single-Peptide Pens

Consider Tirsema 44 only if you have already completed a full titration on a single-peptide GLP-1 and stalled. For first-time users, a tirzepatide-only pen is the more sensible entry point because it allows tolerance to build to one peptide before adding a second. The table below sets out how the pens stocked on Beskinny differ on peptide content, receptor targets, and intended user.

Pen	Peptide(s)	Total dose per pen	Receptor targets	Frequency	Best-fit user
HD Tirsema 44	Tirzepatide + semaglutide	40 mg + 4 mg	GIP + GLP-1 (dual agonist) + selective GLP-1	Weekly	Plateaued on single-peptide therapy (combination is investigational)
HD Labs Tirzepatide 30 Pen	Tirzepatide	30 mg	GIP + GLP-1 (dual agonist)	Weekly	Mid-tier user titrating up from semaglutide
Body Pharm Tirzepatide 30 Pen	Tirzepatide	30 mg	GIP + GLP-1	Weekly	In-catalogue tirzepatide-only option
Body Pharm Tirzepatide 60 Pen	Tirzepatide	60 mg	GIP + GLP-1	Weekly	Experienced tirzepatide user at higher titration

Who should not start with Tirsema 44

GLP-1-naive users, anyone with a prior history of severe GI side effects (persistent vomiting, pancreatitis), and users who have not completed at least 8–12 weeks on a single-peptide pen should not begin here. Raising GLP-1 receptor occupancy beyond what tirzepatide alone delivers is expected to increase nausea risk during GLP-1-naive titration. The full HD Labs single-peptide range is browsable at the HD Labs brand page if a lower-intensity starting point fits your profile better.

Dosing Protocol and Escalation Schedule

No HD Labs Tirsema 44 product insert is publicly available as of 2026, so the schedule below is extrapolated from the FDA-approved tirzepatide prescribing information and standard semaglutide titration. It is not a validated protocol for the combined product. Confirm starting dose, step-up intervals, and maximum with your dispensing pharmacist or prescriber before use.

A conservative weekly escalation, in tirzepatide-equivalent terms, follows the approved tirzepatide dose-escalation pattern:

1. Weeks 1–4: 2.5 mg equivalent once weekly. Tolerance check, not a therapeutic dose.
2. Weeks 5–8: 5 mg equivalent once weekly.
3. Weeks 9–12: 7.5 mg equivalent once weekly if GI symptoms are controlled.
4. Weeks 13–16: 10 mg equivalent once weekly.
5. Week 17 onward: step to 12.5 mg or 15 mg equivalent only under clinician supervision. Because semaglutide adds to the GLP-1 load, the practical ceiling may be lower than tirzepatide monotherapy at the HD Labs Tirzepatide 30 Pen or Body Pharm Tirzepatide 30 Pen equivalent dose. This is a theoretical expectation, not a trial-validated figure.

Injection sites and missed doses

Rotate between abdomen (avoiding a 5 cm radius around the navel), front of thigh, and back of upper arm. Don’t inject the same spot two weeks running — repeated injection at one site can cause lipohypertrophy, reducing absorption. If a dose is missed and the next scheduled dose is more than 72 hours away, take it as soon as possible. If less than 72 hours away, skip it and resume the normal weekly schedule.

Managing GI side effects

Mild to moderate nausea typically peaks in the 48 hours after injection and often settles within a few weeks of each new dose as the body adapts to sustained GLP-1 receptor occupancy. Eat smaller, lower-fat meals, stay hydrated, and hold escalation if vomiting or diarrhoea persists beyond 72 hours. Severe abdominal pain radiating to the back warrants stopping the pen and seeking medical review: acute pancreatitis is a recognised warning for GLP-1 receptor agonists.

This protocol is informational. A registered prescriber in South Africa must authorise your titration; tirzepatide and semaglutide are Schedule 4 medicines.

Storage, Handling, and Shelf Life

Store the HD Tirsema 44 Pen in a fridge at 2–8°C until first use, then keep it below 30°C and away from direct light for the in-use period. Do not freeze the pen. Freezing damages both peptides irreversibly because ice-crystal formation disrupts the protein structure. A thawed pen should be discarded even if it looks normal.

Injectable tirzepatide and semaglutide products generally carry an in-use stability window of a few weeks at room temperature under their approved labelling, but the HD Labs Tirsema 44 insert is not publicly accessible. Verify the printed expiry and in-use window on your specific pen rather than relying on a general figure.

Visual checks before each dose

The solution should be clear and colourless. Discard the pen if you see cloudiness, floating particulates, a yellow or brown tint, or if the cartridge has been left above 30°C for longer than 24 hours. These signs can indicate peptide degradation or contamination. A pen that has been frozen, dropped hard, or left in a hot car should not be injected.

Travel and dispatch

For travel, carry the pen in an insulated pouch with a cool pack (not in direct contact with ice) and keep it in cabin luggage, never in the hold where temperatures can drop below freezing. Beskinny dispatches HD Labs pens with cold-chain packaging from Johannesburg, which preserves the 2–8°C range during typical 1–3 day courier transit within South Africa. Refrigerate immediately on arrival. If you are comparing storage practicalities against single-peptide options, the HD Labs Tirzepatide 30 Pen and Body Pharm Tirzepatide 30 Pen follow the same cold-chain and in-use handling rules.

Who Should Use the Tirsema 44 Pen?

The Tirsema 44 pen is aimed at adults who have already trialled a single-peptide GLP-1 or dual GIP/GLP-1 therapy for 8–12 weeks and have not reached their target weight or metabolic goals. The dual-peptide approach is a mechanistic step-up idea when monotherapy plateaus — but remember the combination itself is unstudied. If you are GLP-1 naive, starting with the HD Labs Tirzepatide 30 Pen or Body Pharm Tirzepatide 30 Pen is the more sensible entry point, since both peptides in Tirsema 44 sit at the upper end of the dosing range.

Candidate profile

The underlying peptides were studied in adults with BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or dyslipidaemia (SURMOUNT-1; STEP-1). Tolerating weekly subcutaneous injections is a baseline requirement because the medication cannot be taken orally.

Not suitable for

Tirsema 44 is not suitable for anyone with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome, which is a boxed contraindication for GLP-1 and GIP/GLP-1 receptor agonists. It is also unsuitable for those with a prior episode of pancreatitis, current pregnancy or breastfeeding, or known hypersensitivity to tirzepatide or semaglutide. Adults under 18, and those with severe gastroparesis or active gallbladder disease, should avoid it because these conditions can be worsened by delayed gastric emptying or biliary stasis.

Discuss the pen with a doctor or pharmacist registered in South Africa before ordering, since both peptides are Schedule 4 medicines requiring a prescription.

How to Buy the HD Tirsema 44 Pen in South Africa

Order the HD Tirsema 44 Pen directly from beskinny.store (from R2400 per pen; price current as of 2026 and subject to change — see the live price on the product page). Add to cart, check out with card or EFT, and your pen ships nationwide across South Africa in discreet cold-chain packaging, typically dispatched within 1–2 business days of payment clearing.

Beskinny is a dedicated weight-loss peptide retailer stocking HD Labs, Body Pharm, and other compounded brands. Browse the full weight-loss injections category or the HD Labs brand page to compare before committing. Single-peptide buyers usually weigh up the HD Labs Tirzepatide 30 Pen or Body Pharm Tirzepatide 30 Pen. Because the tirzepatide + semaglutide combination is not SAHPRA-registered, confirm your prescription status with the dispensing pharmacist before checkout.

Frequently Asked Questions

Is Tirsema 44 an approved, registered medicine?

No. Tirsema 44 is a compounded HD Labs pen combining 40 mg tirzepatide with 4 mg semaglutide in one device. The individual peptides are studied and, elsewhere, approved as separate single-molecule products, but the tirzepatide + semaglutide combination has not been evaluated in a published clinical trial and is not a SAHPRA-registered medicine. It is supplied under South African Schedule 4 compounding rules and should be used only under a registered prescriber.

Can I use Tirsema 44 if I have never used a GLP-1 before?

It is not the recommended starting point for naive users. The combined GIP and GLP-1 receptor load at 40 mg + 4 mg sits well above typical initiation doses. First-time users usually begin on a lower-dose single peptide like the HD Labs Tirzepatide 30 Pen and step up only after tolerating a low weekly tirzepatide dose, allowing the body to adapt to GLP-1 signalling first.

How long does one pen last?

At a weekly maintenance dose drawn from the 44 mg total payload, one Tirsema 44 pen typically covers roughly 4–8 weeks depending on where you sit in the titration schedule. Early titration weeks at lower doses stretch the pen further; maintenance dosing at the upper end shortens it.

What is the difference between Tirsema 44 and HD Labs Tirzepatide 30?

Tirsema 44 contains 40 mg tirzepatide plus 4 mg semaglutide. The HD Labs Tirzepatide 30 Pen contains 30 mg tirzepatide only. The 30 pen activates GIP and GLP-1 receptors via one molecule. Tirsema 44 adds a second, selective GLP-1 agonist with the aim of stronger GLP-1 receptor occupancy alongside GIP activity — but, unlike the single-peptide pen, the combination has no clinical-trial evidence of its own.

Does Beskinny ship the Tirsema 44 pen cold?

Yes. Beskinny dispatches the Tirsema 44 pen nationwide in discreet cold-chain packaging, typically within 1–2 business days of payment clearing.

Next Steps

If you have already completed 8–12 weeks on a single-peptide GLP-1 and have plateaued, consult a registered South African prescriber to discuss whether Tirsema 44 is appropriate for your profile — and note that the combination is investigational and not SAHPRA-registered. If you are new to GLP-1 therapy, start with the HD Labs Tirzepatide 30 Pen or Body Pharm Tirzepatide 30 Pen and titrate gradually before considering a dual-peptide step-up. Either way, confirm your prescription status with the dispensing pharmacist before checkout.

References

1. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine, 2022.
2. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP-1). New England Journal of Medicine, 2021.
3. Tirzepatide injection: Highlights of Prescribing Information. DailyMed, U.S. FDA, 2026.
4. Semaglutide injection: Highlights of Prescribing Information. DailyMed, U.S. FDA, 2026.
5. Registered Health Products. South African Health Products Regulatory Authority (SAHPRA), 2026.
6. A Study of Tirzepatide in Participants With Obesity or Overweight (SURMOUNT-1), NCT04184622. ClinicalTrials.gov.
7. Semaglutide in Adults With Overweight or Obesity (STEP-1), NCT03548935. ClinicalTrials.gov.